$27.63
0.58% yesterday
Nasdaq, Sep 22, 10:00 pm CET
ISIN
IE00B56GVS15
Symbol
ALKS

Alkermes Plc Stock price

$27.63
-2.12 7.13% 1M
-7.16 20.58% 6M
-1.13 3.93% YTD
-0.47 1.67% 1Y
+5.52 24.97% 3Y
+10.75 63.64% 5Y
-37.95 57.87% 10Y
+10.97 65.86% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
-0.16 0.58%

Key metrics

Basic
Market capitalization
$4.6b
Enterprise Value
$3.5b
Net debt
positive
Cash
$1.0b
Shares outstanding
165.1m
Valuation (TTM | estimate)
P/E
13.2 | 21.6
P/S
3.0 | 3.2
EV/Sales
2.4 | 2.5
EV/FCF
7.4
P/B
2.8
Financial Health
Equity Ratio
71.3%
Return on Equity
25.1%
ROCE
21.4%
ROIC
28.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.5b | $1.4b
EBITDA
$380.3m | $358.1m
EBIT
$374.5m | $221.9m
Net Income
$348.1m | $211.6m
Free Cash Flow
$479.5m
Growth (TTM | estimate)
Revenue
-0.2% | -7.1%
EBITDA
-4.7% | -16.2%
EBIT
-0.2% | -47.3%
Net Income
20.6% | -42.4%
Free Cash Flow
46.4%
Margin (TTM | estimate)
Gross
85.1%
EBITDA
25.3% | 24.7%
EBIT
24.9%
Net
23.1% | 14.6%
Free Cash Flow
31.9%
More
EPS
$2.1
FCF per Share
$2.9
Short interest
11.7%
Employees
2k
Rev per Employee
$870.0k
Show more

Is Alkermes Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Alkermes Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Alkermes Plc forecast:

17x Buy
74%
6x Hold
26%

Analyst Opinions

23 Analysts have issued a Alkermes Plc forecast:

Buy
74%
Hold
26%

Financial data from Alkermes Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,505 1,505
0% 0%
100%
- Direct Costs 224 224
11% 11%
15%
1,281 1,281
2% 2%
85%
- Selling and Administrative Expenses 640 640
3% 3%
42%
- Research and Development Expense 261 261
34% 34%
17%
380 380
5% 5%
25%
- Depreciation and Amortization 5.82 5.82
75% 75%
0%
EBIT (Operating Income) EBIT 374 374
0% 0%
25%
Net Profit 348 348
21% 21%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Alkermes Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alkermes Plc Stock News

Neutral
PRNewsWire
11 days ago
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.
Neutral
PRNewsWire
12 days ago
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 — DUBLIN , Sept.
Neutral
Seeking Alpha
14 days ago
Alkermes plc (NASDAQ:ALKS ) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Marcus Yountz - Vice President of Clinical Development Conference Call Participants G...
More Alkermes Plc News

Company Profile

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Richard Pops
Employees 1,800
Founded 2011
Website www.alkermes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today